Current Report Filing (8-k)
August 08 2018 - 3:16PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 8, 2018
SYNTHETIC BIOLOGICS, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
001-12584
|
|
13-3808303
|
(State or other jurisdiction of incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
9605 Medical Center Drive, Suite 270
Rockville, MD 20850
(Address of principal executive offices
and zip code)
Registrant’s telephone number, including
area code: (301) 417-4364
N/A
(Former name or former address, if changed
since last report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
¨
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On August 8, 2018, Synthetic Biologics,
Inc., a Nevada corporation, (the “Registrant”) issued the attached press release that included financial information
for the fiscal quarter ended June 30, 2018. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form
8-K. The information contained in the press release is being furnished to the Securities and Exchange Commission (the “Commission”)
and shall not be deemed incorporated by reference into any of the Registrant’s registration statements or other filings with
the Commission.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 8, 2018
|
SYNTHETIC BIOLOGICS, INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Steven A. Shallcross
|
|
|
|
Name: Steven A. Shallcross
|
|
|
|
Title: Interim Chief Executive Officer and
Chief Financial Officer
|
|
EXHIBIT INDEX
Synthetic Biologics (AMEX:SYN)
Historical Stock Chart
From Apr 2024 to May 2024
Synthetic Biologics (AMEX:SYN)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Synthetic Biologics Inc (American Stock Exchange): 0 recent articles
More Synthetic Biologics, Inc. News Articles